search
Back to results

PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (POETIC-A)

Primary Purpose

Breast Cancer Female

Status
Recruiting
Phase
Phase 3
Locations
United Kingdom
Study Type
Interventional
Intervention
Abemaciclib
Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
Sponsored by
Institute of Cancer Research, United Kingdom
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Cancer Female focused on measuring CDK4/6 inhibitor, ER+, HER2-

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Registration Stage Inclusion Criteria:

  1. Women determined to be postmenopausal according to established local criteria.
  2. Diagnosed operable invasive breast cancer with a clinical/radiological tumour size ≥1.5cm*
  3. Preoperative full assessment completed (including bilateral breast examination and imaging with mammogram +/- ultrasound/MRI as performed locally).
  4. Tumour ER positive. ER positivity is defined as >/=1% cells staining positive (or equivalent Allred Score of ER >/=3 out of 8).
  5. Tumour HER2 negative or HER2 status unknown. HER2 negativity will be defined as per the 2018 ASCO/CAP updated guidelines. Patients whose HER2 status is pending/unknown at the time of registration will be allowed to register to the trial. However, please note that only patients who are confirmed to be HER2 negative will be eligible to join the randomised part.
  6. Received or planned to receive 10 days to 6 months of anastrozole or letrozole prior to surgery.
  7. Written informed consent to enter the registration stage of the trial and to donation of fresh tissue.
  8. The patient has given written informed consent prior to any study-specific procedures and is willing and able to make herself available for the duration of the study and amenable and able to follow study schedule during treatment and follow-up and for the use of routinely collected electronic health and related records.

    • For patients who enter the trial after surgery - patients with a grade 1 tumour at diagnosis will still be eligible for registration if they have Ki67 >/=8% at surgery (following >/=10 days of pre-surgical AI therapy), as measured at the local site, and meet all other eligibility criteria.

Registration Stage Exclusion Criteria:

  1. Men and pre/perimenopausal women.
  2. Grade 1 tumours*
  3. Intended or actual use of HRT or any other oestrogen-containing medication (including vaginal oestrogens) within 4 weeks prior to planned surgery). Note: patient with a Mirena coil in situ at the time of registration are not excluded.
  4. Patients who commenced pre-surgical AI therapy >6 months prior to surgery.
  5. Prior endocrine therapy for breast cancer or breast cancer prevention.
  6. Prior neoadjuvant chemotherapy for breast cancer.
  7. Evidence of metastatic disease.
  8. Locally advanced breast cancer not amenable to surgery.
  9. Bilateral invasive breast cancer (excluding contralateral DCIS/LCIS).
  10. Multiple unilateral tumours with different ER and/or HER2 status. Synchronous DCIS/LCIS, as well as multifocal disease with homogenous ER/HER2 status is allowed if at least one lesion is at least 1.5cm; the largest lesion should be used for sample collection and CRF completion. If ER/HER2 status of smaller foci is unknown at time of registration, patients can be registered; however, note that congruity of receptor status will need to be confirmed by the time of randomisation.
  11. Previous invasive breast cancer except for ipsilateral DCIS or LCIS treated >5 years previously by locoregional therapy alone or contralateral DCIS/LCIS treated by locoregional therapy at any time.
  12. Any invasive malignancy diagnosed within previous 5 years (other than non-melanoma skin cancer or cervical carcinoma in situ).
  13. Any other medical condition likely to exclude the patient from subsequent randomisation stage. (See exclusion criteria: Eligibility for Randomisation).

    • For patients who enter the trial after surgery - patients with a grade 1 tumour at diagnosis will still be eligible for registration if they have Ki67 >/=8% at surgery (following >/=10 days of pre-surgical AI therapy), as measured at the local site, and meet all other eligibility criteria.

Randomisation stage Inclusion Criteria

  1. Patient previously consented and registered for screening component of POETIC A.
  2. Tumour HER2 negative. HER2 negativity will be defined as per the 2018 ASCO/CAP updated guidelines
  3. Centrally confirmed Ki67 >/=8% following 2 weeks of AI.
  4. Aromatase Inhibitor Resistant-CDK4/6 Inhibitor Sensitive (AIR-CIS) signature has been derived in the central laboratory and confirmed to ICR-CTSU.
  5. Patient must have undergone definitive surgery for the primary breast tumour with clear radial margins as judged by the multidisciplinary team.
  6. Surgical staging of the axilla must have been undertaken by sentinel node biopsy, axillary sampling or dissection.
  7. Adjuvant chemotherapy, if prescribed, must have been completed prior to randomisation and patients must have recovered (Common Terminology Criteria for Adverse Events, version 5 [CTCAEv5] Grade </=1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomisation. A washout period of a minimum of 28 days from day 1 of last cycle of treatment is required.
  8. Adjuvant radiotherapy, if prescribed, must have been completed prior to randomisation, and patients must have recovered (Grade </=1) from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomisation.
  9. The patient should be randomised no later than three months after completion of non-endocrine therapy (defined as the final fraction of radiotherapy, Day 1 of the final cycle of chemotherapy or the date of the final surgical procedure)..
  10. The patient is able to swallow oral medications.
  11. The patient has adequate organ function for all of the following criteria defined as; ANC >/= 1.5 × 10e9/L (G-CSF cannot be administered to meet this ANC eligibility criterion) Platelets >/= 100 × 10e9/L Haemoglobin >/= 8g/dL Total bilirubin </= 1.5 × ULN (Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted.) ALT and AST </= 3 × ULN
  12. The patient intends to take adjuvant endocrine therapy for at least 5 years.
  13. The patient has given written informed consent prior to any study-specific procedures (for the randomised intervention part), willing to donate tissue from diagnostic biopsy, and is willing and able to make herself available for the duration of the study and to follow study schedule during treatment and follow-up and for the use of routinely collected electronic health and related records.

Randomisation stage Exclusion Criteria

  1. Patient has received prior CDK4/6 inhibitor.
  2. Any patient with a history of VTE (for example, DVT of the leg or arm and/or PE) will be excluded. Patients with a history of venous catheter occlusion by thrombus that did NOT surround the catheter, and the lumen could be made patent by appropriate measures (for example, saline or thrombolytic agent), are not excluded.
  3. The patient has a serious/or uncontrolled pre-existing medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (such as severe renal impairment, [for example, estimated creatinine clearance <30 mL/min], interstitial lung disease, severe dyspnoea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or pre-existing Crohn's disease or ulcerative colitis or a pre-existing chronic condition resulting in baseline Grade 2 diarrhoea).
  4. The patient has a personal history of any of the following conditions: syncope of cardiovascular aetiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: patients with controlled atrial fibrillation diagnosed more than 30 days prior to randomisation are not excluded.
  5. The patient has had major surgery within 14 days prior to randomisation.
  6. The patient has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to randomisation, or is currently enrolled in any other type of medical research (for example: medical device) judged by the Chief Investigator not to be scientifically or medically compatible with this study.
  7. The patient has active systemic bacterial infections (requiring IV antibiotics at time of initiating study treatment), systemic fungal infection or detectable viral infection (such as known HIV positivity or with known active hepatitis B or C (e.g. hepatitis B surface antigen positive). Screening is not required for enrolment.
  8. Evidence of metastatic disease.
  9. Multiple unilateral tumours with different ER and/or HER2 status (DCIS/LCIS are permitted, and confirmation of congruent ER/HER2 status is not necessary for lesions less than 10mm).

Sites / Locations

  • Royal Cornwall HospitalRecruiting
  • Royal Devon & Exeter HospitalRecruiting
  • Queen Elizabeth HospitalRecruiting
  • Great Western HospitalRecruiting
  • Northampton General HospitalRecruiting
  • Belfast City HospitalRecruiting
  • Forth Valley Royal HospitalRecruiting
  • Royal Surrey County HospitalRecruiting
  • Aberdeen Royal InfirmaryRecruiting
  • Ysbyty GwyneddRecruiting
  • Royal United Hospital BathRecruiting
  • Royal Blackburn HospitalRecruiting
  • Blackpool Victoria HospitalRecruiting
  • Royal Bournemouth HospitalRecruiting
  • Royal Sussex County HospitalRecruiting
  • Burnley General HospitalRecruiting
  • Doncaster Royal Infirmary
  • Dumfries and Galloway Royal InfirmaryRecruiting
  • Ninewells HospitalRecruiting
  • Western General HospitalRecruiting
  • Harrogate District HospitalRecruiting
  • Ipswich HospitalRecruiting
  • Kingston HospitalRecruiting
  • St James's University HospitalRecruiting
  • St John's HospitalRecruiting
  • Barnet and Chase Farm HospitalsRecruiting
  • Charing Cross HospitalRecruiting
  • Royal Free HospitalRecruiting
  • Royal Marsden NHS Foundation TrustRecruiting
  • University College LondonRecruiting
  • North Manchester General HospitalRecruiting
  • The Christie HospitalRecruiting
  • Wythenshawe HospitalRecruiting
  • Milton Keynes University HospitalRecruiting
  • Poole General HospitalRecruiting
  • Royal Berkshire HospitalRecruiting
  • East Surrey HospitalRecruiting
  • Glan ClwydRecruiting
  • Royal Shrewsbury HospitalRecruiting
  • Southampton General HospitalRecruiting
  • University Hospitals of North Tees and HartlepoolRecruiting
  • Royal Marsden HospitalRecruiting
  • Mid Yorkshire -Pinderfields HospitalRecruiting
  • Royal Albert Edward InfirmaryRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Endocrine Therapy only

Endocrine Therapy with abemaciclib

Arm Description

Endocrine therapy prescribed as per standard of care, for an expected duration of at least 5 years, or until evidence of disease recurrence or other discontinuation criteria are met. Choice of endocrine therapy may include non-steroidal aromatase inhibitor (letrozole or anastrozole), steroidal aromatase inhibitor (exemestane), or tamoxifen

Abemaciclib administered at dose of 150mg twice daily (provided as 50mg tablets), for 2 years or until evidence of disease recurrence or other discontinuation criteria are met. Endocrine therapy prescribed as per standard of care, for an expected duration of at least 5 years, or until evidence of disease recurrence or other discontinuation criteria are met. Choice of endocrine therapy may include non-steroidal aromatase inhibitor (letrozole or anastrozole), steroidal aromatase inhibitor (exemestane), or tamoxifen

Outcomes

Primary Outcome Measures

Time to tumour (local or distant disease) recurrence
the time from randomisation to local, regional or distant tumour recurrence or death from breast cancer without prior notification of relapse. Second primary cancers and intercurrent deaths will be treated as censoring events.

Secondary Outcome Measures

Relapse-free-survival
the time from randomisation to local, regional or distant tumour recurrence or death from any cause.
Time to distant recurrence
the time from randomisation to distant tumour recurrence. Second primary cancers and intercurrent deaths will be treated as censoring events
Breast cancer specific survival
time from randomisation to death from breast cancer (with or without prior notification of relapse). Intercurrent deaths will be treated as censoring events.
Overall survival
time from randomisation to death from any cause.
Patient reported quality of life
measured using validated questionnaires which will be defined before the commencement of the relevant sub-study.
Grade 3/4 Adverse Events, SAEs and hospitalisations
assessed by NCI CTCAE v5
Treatment related deaths
defined as death occurring at any time point after randomisation and assessed to be possibly, probably or definitely related to the intervention

Full Information

First Posted
July 6, 2020
Last Updated
January 23, 2023
Sponsor
Institute of Cancer Research, United Kingdom
search

1. Study Identification

Unique Protocol Identification Number
NCT04584853
Brief Title
PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
Acronym
POETIC-A
Official Title
PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 23, 2020 (Actual)
Primary Completion Date
September 30, 2030 (Anticipated)
Study Completion Date
March 31, 2032 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institute of Cancer Research, United Kingdom

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
POETIC-A is a phase 3 trial which targets post-menopausal primary breast cancer patients with a high 5-year risk of relapse as determined by a high Ki67 after 2 weeks aromatase inhibitor therapy pre-surgery. Eligible patients will be randomised to standard adjuvant endocrine therapy alone or standard adjuvant endocrine therapy with a CDK4/6 inhibitor called abemaciclib.
Detailed Description
In women with hormone sensitive early breast cancer, taking a hormone therapy (also known as endocrine therapy) for at least five years after surgery is very effective at reducing the risk of the cancer returning. However, for some women their cancer may eventually become resistant to these drugs. POETIC-A Registration part will identify those who have a higher risk of developing resistance to standard endocrine therapy (ET). At least 8000 women diagnosed with early stage breast cancer and have not yet had surgery to remove the cancer will enter the Registration stage from 80 centres. Study doctors will use aromatase inhibitors (AIs), a type of ET, to treat the cancer for between 2 weeks and 6 months before surgery. A sample will be taken from the cancer during surgery and the study laboratory will measure a biological marker called Ki67. If the level of Ki67 does not drop after 2 weeks of AI treatment, the patient is likely to be less sensitive to endocrine therapy, and the study doctor will explore additional treatments after surgery in the POETIC-A Treatment part. Everyone who agrees to join the Treatment stage (2500 patients) will be randomly put into one of the 2 treatment groups; Group1: ET only; or Group2: ET plus a new drug called abemaciclib. The first aim of the Treatment stage is to confirm whether abemaciclib given in combination with ET is more effective than giving ET alone in preventing the cancer coming back. The study laboratory will perform a second test on the cancer sample, called an AIR-CIS test. This test aims to find out if particular groups of patients based on their tumour biology are more suitable for treatment with abemaciclib. Patients in Group 2 will receive ET plus abemaciclib for 2 years. Patients in both groups will have regular study visits during this period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer Female
Keywords
CDK4/6 inhibitor, ER+, HER2-

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Endocrine Therapy only
Arm Type
Active Comparator
Arm Description
Endocrine therapy prescribed as per standard of care, for an expected duration of at least 5 years, or until evidence of disease recurrence or other discontinuation criteria are met. Choice of endocrine therapy may include non-steroidal aromatase inhibitor (letrozole or anastrozole), steroidal aromatase inhibitor (exemestane), or tamoxifen
Arm Title
Endocrine Therapy with abemaciclib
Arm Type
Experimental
Arm Description
Abemaciclib administered at dose of 150mg twice daily (provided as 50mg tablets), for 2 years or until evidence of disease recurrence or other discontinuation criteria are met. Endocrine therapy prescribed as per standard of care, for an expected duration of at least 5 years, or until evidence of disease recurrence or other discontinuation criteria are met. Choice of endocrine therapy may include non-steroidal aromatase inhibitor (letrozole or anastrozole), steroidal aromatase inhibitor (exemestane), or tamoxifen
Intervention Type
Drug
Intervention Name(s)
Abemaciclib
Other Intervention Name(s)
Verzenios
Intervention Description
Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation
Intervention Type
Drug
Intervention Name(s)
Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
Other Intervention Name(s)
Arimidex, Aromasin, Femara, or Tamoxifen
Intervention Description
Standard of care endocrine therapy for a minimum of 5 years from randomisation
Primary Outcome Measure Information:
Title
Time to tumour (local or distant disease) recurrence
Description
the time from randomisation to local, regional or distant tumour recurrence or death from breast cancer without prior notification of relapse. Second primary cancers and intercurrent deaths will be treated as censoring events.
Time Frame
from randomisation until tumour recurrence or patient death, assessed up to 5 years
Secondary Outcome Measure Information:
Title
Relapse-free-survival
Description
the time from randomisation to local, regional or distant tumour recurrence or death from any cause.
Time Frame
from randomisation until relapse or patient death, assessed up to 5 years
Title
Time to distant recurrence
Description
the time from randomisation to distant tumour recurrence. Second primary cancers and intercurrent deaths will be treated as censoring events
Time Frame
from randomisation until distant recurrence or patient death, assessed up to 5 years
Title
Breast cancer specific survival
Description
time from randomisation to death from breast cancer (with or without prior notification of relapse). Intercurrent deaths will be treated as censoring events.
Time Frame
from randomisation until patient death from breast cancer, assessed up to 5 years
Title
Overall survival
Description
time from randomisation to death from any cause.
Time Frame
from randomisation until patient death, assessed up to 5 years
Title
Patient reported quality of life
Description
measured using validated questionnaires which will be defined before the commencement of the relevant sub-study.
Time Frame
5 years from randomisation
Title
Grade 3/4 Adverse Events, SAEs and hospitalisations
Description
assessed by NCI CTCAE v5
Time Frame
from randomisation up to 28 days after treatment discontinuation
Title
Treatment related deaths
Description
defined as death occurring at any time point after randomisation and assessed to be possibly, probably or definitely related to the intervention
Time Frame
5 years from randomisation

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Registration Stage Inclusion Criteria: Women determined to be postmenopausal according to established local criteria. Diagnosed operable invasive breast cancer with a clinical/radiological tumour size ≥1.5cm* Preoperative full assessment completed (including bilateral breast examination and imaging with mammogram +/- ultrasound/MRI as performed locally). Tumour ER positive. ER positivity is defined as >/=1% cells staining positive (or equivalent Allred Score of ER >/=3 out of 8). Tumour HER2 negative or HER2 status unknown. HER2 negativity will be defined as per the 2018 ASCO/CAP updated guidelines. Patients whose HER2 status is pending/unknown at the time of registration will be allowed to register to the trial. However, please note that only patients who are confirmed to be HER2 negative will be eligible to join the randomised part. Received or planned to receive 10 days to 6 months of anastrozole or letrozole prior to surgery. Written informed consent to enter the registration stage of the trial and to donation of fresh tissue. The patient has given written informed consent prior to any study-specific procedures and is willing and able to make herself available for the duration of the study and amenable and able to follow study schedule during treatment and follow-up and for the use of routinely collected electronic health and related records. For patients who enter the trial after surgery - patients with a grade 1 tumour at diagnosis will still be eligible for registration if they have Ki67 >/=8% at surgery (following >/=10 days of pre-surgical AI therapy), as measured at the local site, and meet all other eligibility criteria. Registration Stage Exclusion Criteria: Men and pre/perimenopausal women. Grade 1 tumours* Intended or actual use of HRT or any other oestrogen-containing medication (including vaginal oestrogens) within 4 weeks prior to planned surgery). Note: patient with a Mirena coil in situ at the time of registration are not excluded. Patients who commenced pre-surgical AI therapy >6 months prior to surgery. Prior endocrine therapy for breast cancer or breast cancer prevention. Prior neoadjuvant chemotherapy for breast cancer. Evidence of metastatic disease. Locally advanced breast cancer not amenable to surgery. Bilateral invasive breast cancer (excluding contralateral DCIS/LCIS). Multiple unilateral tumours with different ER and/or HER2 status. Synchronous DCIS/LCIS, as well as multifocal disease with homogenous ER/HER2 status is allowed if at least one lesion is at least 1.5cm; the largest lesion should be used for sample collection and CRF completion. If ER/HER2 status of smaller foci is unknown at time of registration, patients can be registered; however, note that congruity of receptor status will need to be confirmed by the time of randomisation. Previous invasive breast cancer except for ipsilateral DCIS or LCIS treated >5 years previously by locoregional therapy alone or contralateral DCIS/LCIS treated by locoregional therapy at any time. Any invasive malignancy diagnosed within previous 5 years (other than non-melanoma skin cancer or cervical carcinoma in situ). Any other medical condition likely to exclude the patient from subsequent randomisation stage. (See exclusion criteria: Eligibility for Randomisation). For patients who enter the trial after surgery - patients with a grade 1 tumour at diagnosis will still be eligible for registration if they have Ki67 >/=8% at surgery (following >/=10 days of pre-surgical AI therapy), as measured at the local site, and meet all other eligibility criteria. Randomisation stage Inclusion Criteria Patient previously consented and registered for screening component of POETIC A. Tumour HER2 negative. HER2 negativity will be defined as per the 2018 ASCO/CAP updated guidelines Centrally confirmed Ki67 >/=8% following 2 weeks of AI. Aromatase Inhibitor Resistant-CDK4/6 Inhibitor Sensitive (AIR-CIS) signature has been derived in the central laboratory and confirmed to ICR-CTSU. Patient must have undergone definitive surgery for the primary breast tumour with clear radial margins as judged by the multidisciplinary team. Surgical staging of the axilla must have been undertaken by sentinel node biopsy, axillary sampling or dissection. Adjuvant chemotherapy, if prescribed, must have been completed prior to randomisation and patients must have recovered (Common Terminology Criteria for Adverse Events, version 5 [CTCAEv5] Grade </=1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomisation. A washout period of a minimum of 28 days from day 1 of last cycle of treatment is required. Adjuvant radiotherapy, if prescribed, must have been completed prior to randomisation, and patients must have recovered (Grade </=1) from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomisation. The patient should be randomised no later than three months after completion of non-endocrine therapy (defined as the final fraction of radiotherapy, Day 1 of the final cycle of chemotherapy or the date of the final surgical procedure).. The patient is able to swallow oral medications. The patient has adequate organ function for all of the following criteria defined as; ANC >/= 1.5 × 10e9/L (G-CSF cannot be administered to meet this ANC eligibility criterion) Platelets >/= 100 × 10e9/L Haemoglobin >/= 8g/dL Total bilirubin </= 1.5 × ULN (Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted.) ALT and AST </= 3 × ULN The patient intends to take adjuvant endocrine therapy for at least 5 years. The patient has given written informed consent prior to any study-specific procedures (for the randomised intervention part), willing to donate tissue from diagnostic biopsy, and is willing and able to make herself available for the duration of the study and to follow study schedule during treatment and follow-up and for the use of routinely collected electronic health and related records. Randomisation stage Exclusion Criteria Patient has received prior CDK4/6 inhibitor. Any patient with a history of VTE (for example, DVT of the leg or arm and/or PE) will be excluded. Patients with a history of venous catheter occlusion by thrombus that did NOT surround the catheter, and the lumen could be made patent by appropriate measures (for example, saline or thrombolytic agent), are not excluded. The patient has a serious/or uncontrolled pre-existing medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (such as severe renal impairment, [for example, estimated creatinine clearance <30 mL/min], interstitial lung disease, severe dyspnoea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or pre-existing Crohn's disease or ulcerative colitis or a pre-existing chronic condition resulting in baseline Grade 2 diarrhoea). The patient has a personal history of any of the following conditions: syncope of cardiovascular aetiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: patients with controlled atrial fibrillation diagnosed more than 30 days prior to randomisation are not excluded. The patient has had major surgery within 14 days prior to randomisation. The patient has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to randomisation, or is currently enrolled in any other type of medical research (for example: medical device) judged by the Chief Investigator not to be scientifically or medically compatible with this study. The patient has active systemic bacterial infections (requiring IV antibiotics at time of initiating study treatment), systemic fungal infection or detectable viral infection (such as known HIV positivity or with known active hepatitis B or C (e.g. hepatitis B surface antigen positive). Screening is not required for enrolment. Evidence of metastatic disease. Multiple unilateral tumours with different ER and/or HER2 status (DCIS/LCIS are permitted, and confirmation of congruent ER/HER2 status is not necessary for lesions less than 10mm).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Doris Lanz
Phone
+44(0)2034376858
Email
poetic-a-icrctsu@icr.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen Johnston
Organizational Affiliation
Royal Marsden NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal Cornwall Hospital
City
Truro
State/Province
Cornwall
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Duncan Wheatley
Facility Name
Royal Devon & Exeter Hospital
City
Exeter
State/Province
Devon
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Douglas Ferguson
Facility Name
Queen Elizabeth Hospital
City
King's Lynn
State/Province
England
ZIP/Postal Code
PE30 4ET
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicola Ainsworth, MD
Facility Name
Great Western Hospital
City
Swindon
State/Province
England
ZIP/Postal Code
SN3 6BB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Kendal, MD
Facility Name
Northampton General Hospital
City
Northampton
State/Province
Northants
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Harieta Garofide
Facility Name
Belfast City Hospital
City
Belfast
State/Province
Northern Ireland
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonathan Thompson
Phone
028 95 047850
Email
jonathan.thompson@belfasttrust.hscni.net
First Name & Middle Initial & Last Name & Degree
Stuart McIntosh
First Name & Middle Initial & Last Name & Degree
Jane Hurwitz
Facility Name
Forth Valley Royal Hospital
City
Larbert
State/Province
Scotland
ZIP/Postal Code
FK5 4WR
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Brogan
Phone
01324 566316
Email
stephanie.brogan@nhs.scot
First Name & Middle Initial & Last Name & Degree
Anne Todd
Phone
01324 566316
Email
anne.todd@nhs.scot
First Name & Middle Initial & Last Name & Degree
Lucy Khan
First Name & Middle Initial & Last Name & Degree
Husam Marashi
Facility Name
Royal Surrey County Hospital
City
Guildford
State/Province
Surrey
ZIP/Postal Code
GU2 7XX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claire Merrick
Phone
01483571122
Email
c.merrick1@nhs.net
First Name & Middle Initial & Last Name & Degree
R&D
Email
mailto:rsc-tr.researchanddevelopment@nhs.net
First Name & Middle Initial & Last Name & Degree
Felicity Paterson
First Name & Middle Initial & Last Name & Degree
Tracey Irvine
Facility Name
Aberdeen Royal Infirmary
City
Aberdeen
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ravi Sharma, MD
Facility Name
Ysbyty Gwynedd
City
Bangor
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Catherine Bale
Facility Name
Royal United Hospital Bath
City
Bath
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mark Beresford
Facility Name
Royal Blackburn Hospital
City
Blackburn
ZIP/Postal Code
BB2 3HH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christina Yip
First Name & Middle Initial & Last Name & Degree
Christina Yip
Facility Name
Blackpool Victoria Hospital
City
Blackpool
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pavel Bezecny
Facility Name
Royal Bournemouth Hospital
City
Bournemouth
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anthony Skene
Facility Name
Royal Sussex County Hospital
City
Brighton
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rathi Rathinaezhil
Facility Name
Burnley General Hospital
City
Burnley
ZIP/Postal Code
BB10 2PQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christina Yip
First Name & Middle Initial & Last Name & Degree
Christina Yip
Facility Name
Doncaster Royal Infirmary
City
Doncaster
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Dumfries and Galloway Royal Infirmary
City
Dumfries
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aisling Hennessy
Facility Name
Ninewells Hospital
City
Dundee
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jane Macaskill
Facility Name
Western General Hospital
City
Edinburgh
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caroline Michie
Facility Name
Harrogate District Hospital
City
Harrogate
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Biswajit Ray
Facility Name
Ipswich Hospital
City
Ipswich
ZIP/Postal Code
IP4 5PD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul Ridley
Phone
01473 704389
Email
PAUL.RIDLEY@ESNEFT.NHS.UK
First Name & Middle Initial & Last Name & Degree
Ramachandran Venkitaraman
Facility Name
Kingston Hospital
City
Kingston Upon Thames
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marina Parton
Facility Name
St James's University Hospital
City
Leeds
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Baek Kim
Facility Name
St John's Hospital
City
Livingston
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caroline Michie
Facility Name
Barnet and Chase Farm Hospitals
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Judy King
Facility Name
Charing Cross Hospital
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Susan Cleator
Facility Name
Royal Free Hospital
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amna Sheri
Facility Name
Royal Marsden NHS Foundation Trust
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alistair Ring
Facility Name
University College London
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elsa Papadimitraki
Facility Name
North Manchester General Hospital
City
Manchester
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nabila Nasir
Facility Name
The Christie Hospital
City
Manchester
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sacha Howell
Facility Name
Wythenshawe Hospital
City
Manchester
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cliona Kirwan
Facility Name
Milton Keynes University Hospital
City
Milton Keynes
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hany Eldeeb
Facility Name
Poole General Hospital
City
Poole
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anthony Skene
Facility Name
Royal Berkshire Hospital
City
Reading
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Madhumita Bhattacharyya
Facility Name
East Surrey Hospital
City
Redhill
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jagdeep Singh
Facility Name
Glan Clwyd
City
Rhyl
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jill Bishop
Facility Name
Royal Shrewsbury Hospital
City
Shrewsbury
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Pettit
Facility Name
Southampton General Hospital
City
Southampton
ZIP/Postal Code
SO166YD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Lowry
Phone
023 8120 4618
Email
Jenny.lowry@uhs.nhs.uk
First Name & Middle Initial & Last Name & Degree
Ramsey Cutress
First Name & Middle Initial & Last Name & Degree
Ellen Copson
Facility Name
University Hospitals of North Tees and Hartlepool
City
Stockton-on-Tees
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Janine Graham
First Name & Middle Initial & Last Name & Degree
Dave Fung
Facility Name
Royal Marsden Hospital
City
Sutton
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alistair Ring
Facility Name
Mid Yorkshire -Pinderfields Hospital
City
Wakefield
ZIP/Postal Code
WF1 4DG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zbigniew Kryjak
Facility Name
Royal Albert Edward Infirmary
City
Wigan
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elena Takeuchi, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The datasets generated and/or analysed during the study will be available on request from the POETIC-A trial team via poetic-a-icrctsu@icr.ac.uk via completion of a data access request form after such time that the primary analysis publication and any other key analyses have been completed. Optional advanced consent/authorisation for the possible future sharing of information collected about patients will be obtained at study entry.
IPD Sharing Time Frame
Data will be shared once primary results have been published and other key analyses have been completed.
IPD Sharing Access Criteria
Access will need to be requested via the institution's data access request form (available upon request from poetic-a-icrctsu@icr.ac.uk).

Learn more about this trial

PreOperative Endocrine Therapy for Individualised Care With Abemaciclib

We'll reach out to this number within 24 hrs